로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
    11.
    发明公开
    로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물 失效
    罗丹明衍生物,其制备方法和含有该衍生物的药物组合物

    公开(公告)号:KR1020070074250A

    公开(公告)日:2007-07-12

    申请号:KR1020060002175

    申请日:2006-01-09

    CPC classification number: C07D277/20 C07D417/12

    Abstract: A rhodanine derivative or a pharmaceutically acceptable salt is provided to inhibit the activity of phosphatase, thereby being usefully used for treating diseases such as autoimmune diseases, diabetes, damaged glucose resistance, insulin resistance, obesity, cancer, and malignant diseases. The rhodanine derivative is represented by the formula(1), wherein R1 is alkoxy, arylalkoxy, substituted arylalkoxy, heteroaryl alkoxy, substituted heteroaryl alkoxy, heteroaryl alkyl alkoxy, aryl oxy alkoxy, substituted aryl oxy alkoxy, heteroaryl oxy alkoxy, substituted heteroaryl oxy alkoxy, heterocyclic alkoxy, amino alkoxy, substituted amino alkoxy, heterocyclic oxy alkoxy, cyclic amino alkoxy, heterocyclic amino alkoxy, alkenyl alkoxy, cyclic amino, heterocyclic amino, substituted heterocyclic amino, nitro, sulfonyl, benzene sulfonyl, or substituted benzenesulfonyl; R2 is H or Br; R3 is H, halo, hydroxy, alkoxyl, substituted alkoxy, substituted aryl oxy, alkyl amino alkoxy, cyclic amino alkoxy, heterocyclic amino alkoxy, substituted heterocyclic amino alkoxy, alkyl amino aryl, alkyl amido alkoxy, aryl amido alkoxy, sulfonyl amino alkoxy, or substituted aryl oxy amido alkoxy; R4 is H, halo, nitro, heterocyclo, alkoxy, aryl alkoxy, or substituted aryl alkoxy; and R5 is H or a group represented by the structural formula(a). The method comprises the steps of: (a) preparing an intermediate represented by the formula(3) from a compound represented by the formula(2) as a starting material; and (b) reacting the intermediate of the formula(3) with rhodanine of the formula(4) in the presence of sodium acetate and acetic acid to prepare the rhodanine derivative of the formula(1).

    Abstract translation: 提供绕丹宁衍生物或药学上可接受的盐以抑制磷酸酶的活性,从而有效地用于治疗诸如自身免疫性疾病,糖尿病,葡萄糖耐药性,胰岛素抵抗,肥胖,癌症和恶性疾病等疾病。 所述绕丹宁衍生物由式(1)表示,其中R 1是烷氧基,芳基烷氧基,取代的芳基烷氧基,杂芳基烷氧基,取代的杂芳基烷氧基,杂芳基烷基烷氧基,芳氧基烷氧基,取代的芳氧基烷氧基,杂芳氧基烷氧基,取代的杂芳基氧基烷氧基 杂环烷氧基,氨基烷氧基,取代氨基烷氧基,杂环氧基烷氧基,环状氨基烷氧基,杂环氨基烷氧基,烯基烷氧基,环状氨基,杂环氨基,取代的杂环氨基,硝基,磺酰基,苯磺酰基或取代的苯磺酰基。 R2是H或Br; R 3是H,卤素,羟基,烷氧基,取代的烷氧基,取代的芳基氧基,烷基氨基烷氧基,环氨基烷氧基,杂环氨基烷氧基,取代的杂环氨基烷氧基,烷基氨基芳基,烷基氨基烷氧基,芳基氨基烷氧基,磺酰氨基烷氧基, 或取代的芳基氧基酰胺基烷氧基; R4是H,卤素,硝基,杂环基,烷氧基,芳基烷氧基或取代的芳基烷氧基; R5为H或结构式(a)所示的基团。 该方法包括以下步骤:(a)由式(2)表示的化合物作为原料制备由式(3)表示的中间体; 和(b)在乙酸钠和乙酸的存在下,使式(3)的中间体与式(4)的绕丹宁反应以制备式(1)的绕丹宁衍生物。

    NMDA수용체길항제로작용하는4-(3-치환-프로필옥시)-퀴놀린-2-카복실산유도체
    13.
    发明授权
    NMDA수용체길항제로작용하는4-(3-치환-프로필옥시)-퀴놀린-2-카복실산유도체 失效
    作为NMDA受体拮抗剂的4-(3-取代的丙氧基) - 喹啉-2-羧酸衍生物

    公开(公告)号:KR100274004B1

    公开(公告)日:2000-12-15

    申请号:KR1019980006274

    申请日:1998-02-26

    Abstract: PURPOSE: Provided are the novel NMDA receptor antagonist, 4-(3-substituted-propyloxy)-quinoline-2-carboxylic acid derivatives and the preparation method thereof. CONSTITUTION: The derivatives are represented as shown in the chemical formula 1, where A represents carbamate, amide, thiourea, sulfonylurea, acylthiourea, thiocarbamate, amidine, guanidine, imidate, thioimidate, phosphorylamide, sulfonamide, sulfonthiourea or amines and R represents alkyl (C1¯C20), aryl (C6¯C12), aralkyl, heterocycles, carbocycles (C3¯C14), fused bicyclic, hydrogen or cyano groups. The synthetic process comprises the steps of alkylating 5,7-dichlorokynurenic acid methylester with 1,3-dibromopropane; substitution of the bromine with NaN3 to make azidomine; reducing the resultant to amine compound with Pd-catalyst; converting to amide with the corresponding isocyanate, thioisocyanate or acid chloride and finally hydrolysing the ester group in the parent moiety to make the compound of formula 1. They are strong and unique antagonist acting on the coupling position of the strychnine non-susceptive glycine in the NMDA receptor complex and penetrate effectively into central nervous system. They are effective in the treatment of neurodegeneration, especially useful for the CNS damages effected by the diseases such as heart attack, low blood sugar, local anemia and heart beat halt arising from the low oxygen concentration caused by the external wounds or anemia.

    Abstract translation: 目的:提供新型NMDA受体拮抗剂4-(3-取代 - 丙氧基) - 喹啉-2-羧酸衍生物及其制备方法。 构成:衍生物如化学式1所示,其中A表示氨基甲酸酯,酰胺,硫脲,磺酰脲,酰基硫脲,硫代氨基甲酸酯,脒,胍,亚氨酸酯,硫代亚氨酸酯,磷酰胺,磺酰胺,磺酰硫脲或胺,R代表烷基 C 20),芳基(C 6 -C 12),芳烷基,杂环,碳环(C 3 -C 14),稠合双环,氢或氰基。 该合成方法包括使5,7-二氯喹诺酮酸甲酯与1,3-二溴丙烷烷基化的步骤; 用NaN3取代溴以制备叠氮胺; 用Pd催化剂将产物还原成胺化合物; 用相应的异氰酸酯,硫代异氰酸酯或酰氯转化成酰胺,最后水解母体部分中的酯基以制备式1的化合物。它们是强力和独特的拮抗剂作用于士的宁非感受性甘氨酸的偶联位置 NMDA受体复合物并有效渗入中枢神经系统。 它们有效治疗神经变性,特别适用于由外部伤口或贫血引起的低氧浓度引起的心脏病,低血糖,局部贫血和心跳停止等疾病所致的CNS损伤。

    NMDA 수용체 길항제로 작용하는 4-치환-퀴놀린-2-카복실산 유도체
    14.
    发明公开
    NMDA 수용체 길항제로 작용하는 4-치환-퀴놀린-2-카복실산 유도체 失效
    作为NMDA受体拮抗剂的4-取代 - 喹啉-2-羧酸衍生物

    公开(公告)号:KR1019990071056A

    公开(公告)日:1999-09-15

    申请号:KR1019980006275

    申请日:1998-02-26

    Abstract: 본 발명은 하기 화학식 1의 4-치환-퀴놀린-2-카복실산 유도체, 그 제조방법 및 NMDA 수용체 복합체에 있는 스트리키닌 (strychinine) 비감수성 글리신 결합자리에 작용하는 강력하면서 특이성을 갖는 길항제 (antagonist)로서의 용도에 관한 것이다. 본 발명의 화합물은 신경퇴행성 질환의 치료 및 예방에 유용하다. 특히, 본 발명의 화합물은 뇌졸증, 저혈당증, 국소빈혈, 심장박동정지, 외상과 같은 빈혈이나 저산소증의 결과로서 야기되는 중추신경계의 손상을 줄이는데 유용하다. 또한, 본 발명의 화합물은 간질, 알츠하이머병, 헌팅톤병 및 파킨슨씨병을 포함하는 만성 신경퇴행성 질환의 예방 및 치료에 유용하다. 또한, 본 발명의 화합물은 항경련제, 진통제, 항우울증 치료제, 항불안 치료제 및 항정신분열증 치료제로 사용된다.


    (상기 R
    1 및 R
    2 는 명세서에 정의한 바와 같다.)

Patent Agency Ranking